Drugs Made In America Acquisition II Corp. (DMII) shareholders
Close on Nov 17, 2026Market cap $140.36MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Drugs Made In America Acquisition II LLC Joint filing with Lynn Stockwell (10.20%) | 6,708,333 | 10.20% | 13D (active) | Oct 1, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DMII | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Karpus Management, Inc. | 2,787,998 | – | $28.05M | +190,075 | 0.81% |
| Magnetar Financial LLC | 2,700,000 | – | $27.16M | – | 0.25% |
| MMCAP International Inc. SPC | 2,700,000 | – | $27.16M | – | 2.30% |
| Glazer Capital, LLC | 2,343,278 | – | $23.57M | −6,483 | 0.58% |
| Highbridge Capital Management LLC | 2,241,215 | – | $22.57M | +2,016,211 | 0.55% |
| Millennium Management LLC | 1,993,558 | – | $20.06M | +17,133 | 0.01% |
| Hudson Bay Capital Management LP | 1,969,030 | – | $19.81M | – | 0.05% |
| Wolverine Asset Management LLC | 1,855,222 | – | $18.66M | +59,931 | 0.16% |
| Polar Asset Management Partners Inc. | 1,500,000 | – | $15.09M | – | 0.25% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 1,500,000 | – | $15.09M | – | 0.21% |
| D. E. Shaw & Co., Inc. | 1,475,000 | – | $14.84M | +84,900 | 0.01% |
| AQR Arbitrage LLC | 1,131,266 | – | $11.38M | +18,876 | 0.16% |
| Aristeia Capital LLC | 1,100,000 | – | $11.07M | – | 0.14% |
| Crossingbridge Advisors, LLC | 1,100,000 | – | $11.07M | +750,000 | 1.95% |
| First Trust Capital Management L.P. | 1,067,798 | – | $10.74M | – | 0.63% |
| Davidson Kempner Capital Management LP | 1,000,000 | – | $10.06M | – | 0.12% |
| OMERS ADMINISTRATION Corp | 1,000,000 | – | $10.06M | – | 0.06% |
| Picton Mahoney Asset Management | 888,000 | – | $8.93M | +13,000 | 0.07% |
| Two Sigma Investments, LP | 886,544 | – | $8.92M | – | 0.01% |
| Moore Capital Management, LP | 750,000 | – | $7.55M | – | 0.11% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 69 | 46M | 5 / 15 | 14 / 4 | 6M | 4M |
| Q1 2026 | 68 | 44M | 19 / 11 | 16 / 2 | 12M | 3M |
| Q4 2025 | 51 | 35M | 51 / 0 | 0 / 0 | 35M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
7 funds held DMII in Q2 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of DMII | Value | % of fund | As of |
|---|---|---|---|---|---|
| CrossingBridge Low Duration High Income Fund | 1,073,700 | – | $10.80M | 0.60% | Jun 30, 2026 |
| First Trust Merger Arbitrage Fund | 913,211 | – | $9.19M | 0.56% | Jun 30, 2026 |
| First Trust Multi-Strategy Fund | 142,639 | – | $1.43M | 0.11% | Jun 30, 2026 |
| Destinations Low Duration Fixed Income Fund | 26,300 | – | $264.58K | 0.09% | May 31, 2026 |
| Global Multi-Strategy Fund | 14,179 | – | $142.64K | 0.03% | May 31, 2026 |
| The SPAC and New Issue ETF | 10,769 | – | $108.34K | 1.32% | Jun 30, 2026 |
| Robinson Opportunistic Income Fund | 10,000 | – | $100.60K | 0.94% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Lynn Stockwell | CEO and Exe. Chair of Board, Director, 10% owner | 14,675,000 | Oct 1, 2025 |
| Glenn C. Worman | CFO | 100,000 | Oct 1, 2025 |
| Catherine Do | Director | 100,000 | Oct 17, 2025 |
| Myron W. Shulgan | Director | 100,000 | Oct 2, 2025 |
| Sridhar G. Prasad | Director | 100,000 | Oct 1, 2025 |
| Made In America Acquisition II LLC Drugs | 10% owner | 6,708,333 | Oct 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Catherine Do Director | Sep 26, 2025 | Other | +100,000 | – | – | 100,000 |
| Myron W. Shulgan Director | Sep 26, 2025 | Other | +100,000 | – | – | 100,000 |
| Lynn Stockwell CEO and Exe. Chair of Board, Director, 10% owner | Sep 26, 2025 | Other | −400,000 | – | – | 14,675,000 |
| Lynn Stockwell CEO and Exe. Chair of Board, Director, 10% owner | Sep 26, 2025 | Sale | −7,966,667 | – | – | 6,708,333 |
| Lynn Stockwell CEO and Exe. Chair of Board, Director, 10% owner | Sep 26, 2025 | Buy | +700,000 | – | – | 15,075,000 |
| Sridhar G. Prasad Director | Sep 26, 2025 | Other | +100,000 | – | – | 100,000 |
| Glenn C. Worman CFO | Sep 26, 2025 | Other | +100,000 | – | – | 100,000 |
| Made In America Acquisition II LLC Drugs 10% owner | Sep 26, 2025 | Sale | −7,966,667 | – | – | 6,708,333 |
| Made In America Acquisition II LLC Drugs 10% owner | Sep 26, 2025 | Other | −400,000 | – | – | 14,675,000 |
| Made In America Acquisition II LLC Drugs 10% owner | Sep 26, 2025 | Buy | +700,000 | – | – | 15,075,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 11 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Drugs Made In America Acquisition II's stock actually held short. Settlement fails (shares not delivered on time) peaked at 30,670 shares on Aug 31, 2026 over the last 90 days.
See a number that looks wrong?